OUP (Osage University Partners)

AssetWatch is a leading provider of proactive and predictive maintenance solutions focused on eliminating unplanned downtime for global manufacturers. The company specializes in end-to-end remote condition monitoring, utilizing a network of wireless sensors to collect critical machine health data, which is then analyzed through cloud-based software. Leveraging machine learning algorithms and insights from condition monitoring engineers, AssetWatch transforms data into actionable intelligence, enabling manufacturers to adopt a proactive maintenance culture. Their approach enhances the predictive maintenance process with expert prescriptive recommendations that go beyond standard evaluations, thereby supporting organizations in shifting from reactive to proactive maintenance and reliability strategies.

Virtue AI specializes in AI security and compliance, offering a decentralized, open platform designed for the public good. Their platform provides comprehensive risk assessments for AI applications, ensuring regulatory compliance, and features AI Safety leaderboards for performance benchmarking.

Virtue AI specializes in AI security and compliance, offering a decentralized, open platform designed for the public good. Their platform provides comprehensive risk assessments for AI applications, ensuring regulatory compliance, and features AI Safety leaderboards for performance benchmarking.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.

Overland AI specializes in the development and manufacturing of autonomous navigation technologies for off-road vehicles. The company focuses on creating artificial intelligence-based solutions that enhance navigation and transportation capabilities in mission-critical sectors, including defense and national security. By leveraging machine learning and robotic systems, Overland AI offers modular software solutions that facilitate autonomous operation in challenging environments, such as mines, construction sites, and disaster zones. Its innovations aim to enable users to navigate unimproved roads and complex terrains effectively, thereby improving operational efficiency and safety in diverse applications.

VeraDermics is a dermatology company focused on developing innovative drug delivery systems to address skin conditions, particularly warts. The company has created a dissolvable microneedle patch that allows for the painless administration of immunotherapy, which harnesses the body's immune response to combat the wart virus. This patch is designed for easy application, functioning like a bandage and remaining on the skin for less than an hour. During this time, microneedles made from immune stimulators dissolve from the patch into the skin, providing a sustained release of treatment over several weeks. By offering a straightforward and effective solution, VeraDermics aims to enhance patient experiences and outcomes in dermatological care.

Xscape Photonics specializes in the development of photonic chips aimed at enhancing bandwidth connections within high-performance computing systems and data centers. By leveraging photonics technology, the company creates scalable and energy-efficient solutions that support the demands of next-generation artificial intelligence, machine learning, and simulation hardware. Its photonic chips facilitate improved connections between various computing elements while minimizing power consumption, allowing clients to achieve faster and more efficient communication. Through its innovative approach, Xscape Photonics addresses the growing need for high-speed, sustainable connectivity in the evolving technological landscape.

Quantum Circuits, Inc. is a New Haven, Connecticut-based company that develops, manufactures, and sells superconducting quantum computers. Founded in 2015 by Dr. Robert Schoelkopf, a leading figure in quantum science, the company focuses on creating full-stack quantum computing solutions that prioritize error correction to enhance scalability. Utilizing a dual-rail qubit design, Quantum Circuits aims to reduce the number of physical qubits needed for logical qubit operations by a factor of ten, thereby streamlining the path to fault-tolerant quantum computing. The company's innovative approach allows for efficient quantum computations, making it a significant player in the advancement of quantum technology and its applications in research and industry.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Quintessent Inc., incorporated in 2019 and headquartered in Santa Barbara, California, is a technology company focused on the commercialization of quantum dot-based lasers and photonic integrated circuits. The company develops advanced optical connectivity solutions that utilize the unique properties of quantum dot gain media, combined with co-designed architectures. This innovation enables high-bandwidth communication channels essential for optical networking, large-scale computing systems, and deep learning applications. By leveraging advanced semiconductor materials and laser architectures, Quintessent aims to facilitate the growth of next-generation optical networks and enhance capabilities in sensing and deep learning systems.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. It specializes in developing innovative therapies known as "nocions," which are designed to treat conditions resulting from neurogenic inflammation. These therapies selectively target activated nociceptors, the sensory neurons responsible for pain perception, by utilizing small molecule charged sodium channel blockers. This targeted approach aims to provide robust and sustained relief from serious conditions such as cough, itch, pain, and inflammation, addressing the limitations of traditional small molecule anesthetics.

AssetWatch is a leading provider of proactive and predictive maintenance solutions focused on eliminating unplanned downtime for global manufacturers. The company specializes in end-to-end remote condition monitoring, utilizing a network of wireless sensors to collect critical machine health data, which is then analyzed through cloud-based software. Leveraging machine learning algorithms and insights from condition monitoring engineers, AssetWatch transforms data into actionable intelligence, enabling manufacturers to adopt a proactive maintenance culture. Their approach enhances the predictive maintenance process with expert prescriptive recommendations that go beyond standard evaluations, thereby supporting organizations in shifting from reactive to proactive maintenance and reliability strategies.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to treat aging and age-related diseases. The company utilizes a proprietary systems biology and artificial intelligence platform to identify significant drug targets that influence aging, leveraging extensive datasets to uncover the molecular drivers of age-related pathologies. Among its key offerings is BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor that activates HIF-1 target genes involved in various biological processes, including tissue regeneration and vascular remodeling. Another notable product is BGE-175, an orally administered inhibitor targeting the prostaglandin D2 DP1 signaling pathway, which is linked to an increased risk of mortality and infections, including those associated with immune aging. Founded in 2015 and headquartered in Richmond, California, BioAge Labs is dedicated to harnessing the biology of human aging to create innovative therapies for metabolic and age-related diseases.

Verve Motion specializes in the development of exo-suits designed to assist workers engaged in physically demanding tasks. By integrating advancements in robotics, apparel design, and movement science, the company creates lightweight wearable technology made from flexible textile materials. These exo-suits are designed to adapt to the natural movements of the wearer, delivering support and force at critical moments while maintaining a nonrestrictive fit. Verve Motion's innovative approach aims to enhance workplace safety and comfort, ultimately improving the efficiency of workers in various industries.

Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Kate Therapeutics is a biotechnology company specializing in the development of adeno-associated virus (AAV)-based gene therapies aimed at treating genetically defined muscle and heart diseases. The company employs innovative technology platforms that enhance tissue-specific delivery and gene regulation, effectively addressing the limitations of existing gene therapies. By utilizing novel capsids, Kate Therapeutics achieves superior muscle transduction and liver de-targeting compared to naturally occurring serotypes, facilitating more effective tissue transduction at significantly lower viral doses. This advancement helps to overcome major challenges in muscle gene delivery, ultimately improving treatment outcomes for patients with these specific conditions.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Hack The Box Ltd. is a company that operates an online platform focused on enhancing skills in penetration testing and cybersecurity for individuals, organizations, and educational institutions. Founded in 2017 and based in Folkestone, United Kingdom, the platform facilitates both guided and exploratory learning experiences, allowing users to tackle real-world scenarios through various challenges, including capture the flag-style exercises. This approach enables cybersecurity professionals to improve their offensive and defensive capabilities, better preparing them for diverse cyber challenges. By offering tools for skills development and talent assessment, Hack The Box plays a crucial role in advancing cybersecurity readiness in the modern digital landscape.

Opsys Technology Co., Ltd. specializes in designing and developing optical communication products, focusing on solutions that utilize advanced fiber optics technologies. The company's product offerings include LIDAR systems, RF over fiber links for various applications such as remote antenna and distributed antenna systems, as well as mixed signal solutions for aircraft and maritime environments. Opsys Tech is also active in sectors requiring temperature and strain sensors, as well as data center switching technologies. With a strong emphasis on autonomous vehicle control and intelligent sensors, the company is committed to innovating new applications within the optical market. Founded as a spinoff from a leading optical communication firm, Opsys Tech is based in Holon, Israel, and continues to expand its portfolio to meet the demands of modern technological advancements.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Normunity is a biotechnology company focused on developing a new class of precision immuno-oncology medicines known as immune normalizers. These innovative therapies aim to restore the body's natural immune response against cancer by targeting novel mechanisms that disrupt immune function. Normunity collaborates closely with the lab of Dr. Lieping Chen at Yale School of Medicine, leveraging proprietary discovery platforms to explore complex interactions between cancer and the immune system. The company's emerging pipeline includes drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune activity in cancer patients. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Metalenz, Inc. is a company focused on the research, development, production, and prototyping of innovative optical components. Founded in 2016 and headquartered in Weston, Massachusetts, with a secondary office in San Francisco, California, Metalenz specializes in meta-optics that utilize structured Huygens' surfaces to manipulate the properties of light. Its products include ultra-thin planar optics that facilitate high-resolution, full-color imaging, particularly for consumer electronics such as mobile phones and computers. By developing smaller and lighter alternatives to traditional lenses, Metalenz aims to support businesses in achieving compact and efficient designs for their electronic devices.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

AssetWatch is a leading provider of proactive and predictive maintenance solutions focused on eliminating unplanned downtime for global manufacturers. The company specializes in end-to-end remote condition monitoring, utilizing a network of wireless sensors to collect critical machine health data, which is then analyzed through cloud-based software. Leveraging machine learning algorithms and insights from condition monitoring engineers, AssetWatch transforms data into actionable intelligence, enabling manufacturers to adopt a proactive maintenance culture. Their approach enhances the predictive maintenance process with expert prescriptive recommendations that go beyond standard evaluations, thereby supporting organizations in shifting from reactive to proactive maintenance and reliability strategies.

MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating various neurological diseases. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation (VNS) to address conditions such as tinnitus, chronic pain, and rehabilitation for stroke survivors. Its notable products include the Serenity System, designed specifically for tinnitus treatment, and the Vivistim device, which is FDA approved for assisting ischemic stroke survivors with moderate to severe upper limb impairment. Through its innovative approaches, MicroTransponder aims to enhance recovery and improve the quality of life for individuals affected by these neurological conditions.

Brimstone is a company based in Oakland, California, that specializes in developing a carbon-negative process for producing ordinary Portland cement and supplementary cementitious material. Established in 2019 by Cody Finke and Hugo Leandri, Brimstone's technology employs carbon-free calcium silicate rock as a substitute for limestone, resulting in a product that matches the performance of conventional materials while being cost-competitive at scale. This innovative approach aims to provide the construction industry with a cleaner and more sustainable alternative to traditional cement production methods.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients with neurodegenerative diseases. The company's proprietary platform employs human genetics and patient-derived neuronal cells to identify and validate novel disease pathways related to lysosomal dysfunction or aberrant immune system activation, aiming to translate these findings into clinically effective treatments.

Corelight, Inc. is a provider of network visibility solutions aimed at enhancing cybersecurity for enterprises, government entities, and educational institutions. Founded in 2013 and headquartered in San Francisco, California, the company develops a suite of products that includes Corelight sensors and a fleet management system. Its flagship offering is based on Bro, an open-source network analysis framework that delivers actionable, real-time data, enabling security professionals to comprehensively understand network traffic and effectively detect and mitigate cyber threats. In addition to its headquarters, Corelight maintains offices in Santa Clara, California, and Columbus, Ohio, further supporting its commitment to improving network security across various sectors.

eFFECTOR Therapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, California, that specializes in the development of selective translation regulators for the treatment of cancer and other serious diseases. Founded in 2012, the company is pioneering a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). These drug candidates specifically target the eIF4F complex and its associated kinase, MNK 1/2, which play critical roles in protein synthesis and are linked to prominent cancer signaling pathways such as PI3K-AKT and RAS-MEK. eFFECTOR's products aim to inhibit pathways that drive tumor growth, survival, and immune evasion by regulating the expression of oncoproteins and immunosuppressive proteins. The lead candidate, tomivosertib, is currently being evaluated in a Phase 2b trial for non-small cell lung cancer in combination with pembrolizumab. Additionally, zotatifin, an inhibitor of eIF4A, is undergoing dose-escalation in a Phase 1/2 trial, with further expansion cohorts anticipated. The company also collaborates with Pfizer to advance inhibitors targeting eIF4E.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Verve Motion specializes in the development of exo-suits designed to assist workers engaged in physically demanding tasks. By integrating advancements in robotics, apparel design, and movement science, the company creates lightweight wearable technology made from flexible textile materials. These exo-suits are designed to adapt to the natural movements of the wearer, delivering support and force at critical moments while maintaining a nonrestrictive fit. Verve Motion's innovative approach aims to enhance workplace safety and comfort, ultimately improving the efficiency of workers in various industries.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Hack The Box Ltd. is a company that operates an online platform focused on enhancing skills in penetration testing and cybersecurity for individuals, organizations, and educational institutions. Founded in 2017 and based in Folkestone, United Kingdom, the platform facilitates both guided and exploratory learning experiences, allowing users to tackle real-world scenarios through various challenges, including capture the flag-style exercises. This approach enables cybersecurity professionals to improve their offensive and defensive capabilities, better preparing them for diverse cyber challenges. By offering tools for skills development and talent assessment, Hack The Box plays a crucial role in advancing cybersecurity readiness in the modern digital landscape.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology. The firm is focused on developing innovative antibody-drug conjugate therapies targeting CD46, aimed at treating late-stage multiple myeloma and prostate cancer, among other indications. Utilizing its platform, Fortis Therapeutics prepares antibody-drug conjugates that are designed to effectively address both adenocarcinoma and neuroendocrine cancers, providing oncologists with new therapeutic options for challenging late-stage malignancies.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.

Coho Therapeutics, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, California. The company specializes in developing molecular glue therapeutics aimed at degrading proteins associated with cancer, neurodegeneration, and other serious diseases. By focusing on this innovative approach, Coho Therapeutics seeks to create new classes of medicines that enable healthcare professionals to prevent and treat various lethal conditions.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

Menlo Security, Inc. is a cybersecurity company based in Mountain View, California, that specializes in providing a cloud-based isolation platform designed to protect organizations from cyberattacks. Founded in 2012, the company offers solutions that eliminate the threat of malware from websites, documents, and emails by executing all web content in the cloud. This approach allows users to safely interact with online content without the risk of exposure to malicious threats. Menlo Security serves a diverse clientele, including Fortune 500 companies and financial institutions, through a network of resellers in North America and internationally. The company has expanded its operations across regions including EMEA, Australia, New Zealand, Japan, APAC, and DACH.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Palladio Biosciences, Inc. is a biotechnology company focused on developing innovative medicines for orphan kidney diseases. Established in 2015 and headquartered in Horsham, Pennsylvania, the company is primarily engaged in creating therapeutics for conditions such as polycystic kidney disease (PKD), a serious genetic disorder characterized by the formation of fluid-filled cysts in the kidneys. One of its key products, Lixivaptan, is a selective vasopressin V2 receptor antagonist aimed at treating PKD, helping to prevent disease progression and improve patient outcomes. Palladio Biosciences is dedicated to addressing unmet medical needs in the field of renal diseases.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Nido Biosciences, Inc., incorporated in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company employs a functional genomics discovery platform utilizing human cell lines to identify novel therapeutic targets for various neuromuscular and neurodegenerative conditions. By leveraging advances in neuroscience and human genetics, Nido Biosciences aims to create precise medications that address the underlying biology of these diseases, ultimately restoring healthy cell function and improving patient outcomes.

SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focusing on RISC-V architecture. Established in 2015 and headquartered in San Mateo, California, with additional offices in locations such as Oregon, Texas, India, Taiwan, and France, SiFive provides a range of products including multi-core application processors, embedded microcontrollers, and system-on-chip solutions tailored for various applications such as IoT and wearables. The company emphasizes the use of open-source technology to enable faster and more cost-effective hardware development. By offering software development kits, toolchains, and customized silicon products, SiFive aims to democratize access to advanced semiconductor solutions, accelerating innovation for businesses of all sizes.

Aerovate Therapeutics, founded in 2018 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to improving the lives of patients with rare cardiopulmonary diseases. Its primary focus is AV-101, an inhaled dry powder formulation of imatinib, designed to deliver medication directly to affected lung tissues while minimizing systemic side effects. This innovative approach aims to treat pulmonary arterial hypertension (PAH), a severe and progressive disease.

Censys, Inc. is a technology company that specializes in internet scanning and asset identification solutions. Founded in 2017 and based in Ann Arbor, Michigan, Censys offers an internet intelligence platform that enables organizations to gain a comprehensive real-time view of global networks and devices. Its primary product, Censys, functions as an internet device search engine, allowing users to locate various internet-connected devices, including computers, servers, and smart devices. The platform is utilized for attack surface management, threat hunting, and exposure management, helping businesses discover unknown assets, monitor remote workforces, and identify potential threats. Through its extensive dataset, Censys enhances visibility into vulnerabilities and provides insights into internet-exposed infrastructure, supporting organizations in their security efforts.

Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed to treat acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, thereby allowing for selective targeting of cancer cells while sparing normal cells. This innovative approach aims to minimize the toxicities associated with traditional immunotherapies, such as bispecific antibodies and CAR T cells, which often affect both cancerous and healthy cells. Vor Biopharma's mission is to provide safer and more effective treatment options for patients with hematological malignancies by creating therapies that protect healthy, functional cells from depletion during targeted cancer treatments.

StreetLight Data, Inc. is a technology company specializing in cloud-based analytics solutions that focus on transportation measurement and management for both public and private sectors. Its primary product, StreetLight InSight, is an online platform that analyzes mobility patterns using Big Data by converting anonymous location data from mobile devices into actionable insights. This platform allows users, including transportation engineers and urban planners, to assess mobility across various roads and zones, thereby facilitating informed infrastructure deployment and transportation planning. Additionally, StreetLight Data offers RouteScience, which organizes disparate location data into coherent travel patterns. Founded in 2012 and headquartered in San Francisco, California, the company also has offices in Richmond, Virginia, and Vancouver, Canada, and is dedicated to enhancing smart city initiatives through improved understanding of transportation behaviors.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

IonQ, Inc. is a technology company that specializes in the development of general-purpose quantum information computers utilizing a trapped ion approach. Founded in 2015 and based in College Park, Maryland, IonQ focuses on advancing quantum computing capabilities through qubit replication, optical networkability, and optimized algorithms. The company's quantum computers represent a significant shift from classical computing, effectively addressing limitations associated with superposition and entanglement at the atomic level. IonQ provides access to its quantum processors through cloud platforms, offering quantum-computing-as-a-service (QCaaS) to a wide range of customers. Additionally, the company engages in research and development to enhance its quantum technology and supports clients through consulting services aimed at co-developing algorithms for its quantum systems.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, focused on developing innovative oral therapeutics for autoimmune diseases, particularly inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Founded in 2017, the company aims to address unmet medical needs through its unique approach to treatment, leveraging novel mechanisms of action. Its lead product candidate, NX-13, is a gut-selective NLRX1 agonist designed to modulate immune responses, and it is part of a broader pipeline that includes other internally discovered compounds targeting various pathways at the intersection of immunity and metabolism. Landos Biopharma's commitment to developing first-in-class therapeutics underscores its dedication to improving patient outcomes in the field of autoimmune disorders.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Menlo Security, Inc. is a cybersecurity company based in Mountain View, California, that specializes in providing a cloud-based isolation platform designed to protect organizations from cyberattacks. Founded in 2012, the company offers solutions that eliminate the threat of malware from websites, documents, and emails by executing all web content in the cloud. This approach allows users to safely interact with online content without the risk of exposure to malicious threats. Menlo Security serves a diverse clientele, including Fortune 500 companies and financial institutions, through a network of resellers in North America and internationally. The company has expanded its operations across regions including EMEA, Australia, New Zealand, Japan, APAC, and DACH.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focusing on RISC-V architecture. Established in 2015 and headquartered in San Mateo, California, with additional offices in locations such as Oregon, Texas, India, Taiwan, and France, SiFive provides a range of products including multi-core application processors, embedded microcontrollers, and system-on-chip solutions tailored for various applications such as IoT and wearables. The company emphasizes the use of open-source technology to enable faster and more cost-effective hardware development. By offering software development kits, toolchains, and customized silicon products, SiFive aims to democratize access to advanced semiconductor solutions, accelerating innovation for businesses of all sizes.

Algorithmia, Inc. is a Seattle-based company that specializes in machine learning model deployment and management. Founded in 2013, it provides a platform that enables algorithm developers to create, explore, and share algorithms as web services. The company focuses on automating MLOps, allowing data scientists and developers to efficiently deploy models into production through scalable API endpoints. Algorithmia supports a variety of machine learning frameworks, including TensorFlow, PyTorch, Scikit-learn, and MXNet. Additionally, it hosts the largest public marketplace for algorithms, facilitating a community around building smarter applications. In 2021, Algorithmia was acquired by DataRobot.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

LunaDNA is a community-owned genomic and medical research platform founded by the creators of a leading DNA sequencing company. It facilitates the sharing of health and DNA data, allowing individuals to contribute their personal information for medical research while maintaining ownership of their data. By incentivizing participation, LunaDNA addresses the challenge of data silos that have emerged as personal DNA sequencing has gained popularity. Participants are rewarded with shares in the database, granting them a stake in the profits generated from medical research. These profits are returned to the community as dividends when researchers pay for access to the data. LunaDNA empowers individuals to support health research while ensuring that their contributions benefit the broader community and drive medical discoveries.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing and commercializing innovative products utilizing its proprietary HYALEX technology. This synthetic polymer is specifically designed to mimic the properties of natural cartilage, offering a unique advantage in maintaining low friction and wear under the high loads typically encountered in human joints. The company's goal is to provide solutions for diseased and damaged joints by enabling the replacement of arthritic cartilage while preserving healthy bone. Currently, Hyalex Orthopaedics' products remain in the development stage and have yet to receive regulatory approval for human use.

Vor Biopharma, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing engineered hematopoietic stem cell (eHSC) therapies for cancer treatment. The company's lead product candidate, VOR33, is designed to treat acute myeloid leukemia (AML) and is currently in preclinical development. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, thereby allowing for selective targeting of cancer cells while sparing normal cells. This innovative approach aims to minimize the toxicities associated with traditional immunotherapies, such as bispecific antibodies and CAR T cells, which often affect both cancerous and healthy cells. Vor Biopharma's mission is to provide safer and more effective treatment options for patients with hematological malignancies by creating therapies that protect healthy, functional cells from depletion during targeted cancer treatments.

KenSci Inc. is a healthcare technology company that specializes in developing a machine learning platform aimed at improving risk prediction for healthcare providers and payers. Founded in 2015 and headquartered in Seattle, Washington, with additional offices in Hyderabad and Singapore, KenSci's platform integrates and analyzes data from various sources, including clinical records, claims, and patient-generated information. This enables healthcare organizations to identify clinical, financial, and operational risks, allowing for earlier interventions that can save costs and improve patient outcomes. The platform offers a library of pre-built models and modular solutions, facilitating seamless integration into existing workflows to enhance hospital operations and care coordination. By leveraging Explainable AI, KenSci ensures that its risk-based predictions are both efficient and accountable, ultimately supporting the delivery of better healthcare.

Seismos is a data analytics company specializing in production optimization through proprietary solutions that enable real-time monitoring of underground fluid flow within reservoirs during production. Unlike conventional seismic technologies, which require months for data acquisition and processing, disrupt production, and incur high costs, Seismos offers a more efficient alternative. The company's cloud-based K-wave technology provides real-time information non-invasively, significantly reducing expenses. Additionally, Seismos develops AI-powered sensing systems that utilize non-invasive acoustic sensing and machine learning to detect and predict anomalies in various markets, including upstream, pipelines, and geothermal sectors. This allows organizations to take immediate data-driven actions.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Elementary Robotics, Inc. is a Pasadena, California-based company that specializes in the manufacture of robots designed to assist humans in various industrial applications. Founded in 2017, Elementary Robotics focuses on automating quality assurance and traceability processes within AI-assisted manufacturing. Their robots are utilized to monitor and track the stages of assembly along production lines, serving diverse sectors such as electronics, automotive, medical, consumer packaged goods, and logistics. The company combines hardware and software to create a robust platform that leverages machine learning and computer vision, enabling intelligent automation of workflows. By providing easy-to-use software and deep learning AI, Elementary Robotics aims to enhance efficiency and productivity in repetitive tasks across various industries.

Vector Launch, Inc. is a company based in Tucson, Arizona, that specializes in developing software and launch vehicles tailored for micro and nano satellites. Founded in 2016 by several former members of the original SpaceX team, the company aims to provide affordable and frequent access to space, thereby facilitating innovation for startups in the aerospace sector. Vector Launch operates a vehicle and propulsion engineering facility, with additional offices located in Long Beach and San Jose, California. The company's approach combines low-cost dedicated launches with software-defined satellites, enhancing the speed and accessibility of satellite deployment. Vector Launch's offerings are particularly valuable for micro satellite developers, national security applications, and other government entities, helping to lower the barriers to entry for innovation and commerce in outer space. However, in December 2019, the company filed for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases characterized by high unmet medical needs. Incorporated in 2016 and based in Oakland, California, the company is known for its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapy specifically targets thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance and increasing mitochondrial DNA copy number, Modis Therapeutics' approach seeks to enhance cellular function and prolong the lives of affected patients. As of September 2019, Modis Therapeutics operates as a subsidiary of Zogenix, Inc.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Infinite Uptime, Inc. is a technology company that specializes in providing an integrated industrial solution focused on predictive maintenance for industrial machines. Established in 2015 and headquartered in Berkeley, California, with an additional office and research facility in Pune, India, the company offers a comprehensive industrial data analytics platform that utilizes hardware, cloud analytics, and control software to monitor equipment, diagnose issues, and enhance decision-making processes. The platform leverages artificial intelligence and precision analytics to automatically identify patterns in machine data, calculate overall equipment effectiveness, detect anomalies, and report for compliance. Infinite Uptime serves a variety of sectors including steel, power, cement, chemicals, automotive, and pharmaceuticals, aiming to reduce unplanned downtime and improve operational efficiency across industries.

StreetLight Data, Inc. is a technology company specializing in cloud-based analytics solutions that focus on transportation measurement and management for both public and private sectors. Its primary product, StreetLight InSight, is an online platform that analyzes mobility patterns using Big Data by converting anonymous location data from mobile devices into actionable insights. This platform allows users, including transportation engineers and urban planners, to assess mobility across various roads and zones, thereby facilitating informed infrastructure deployment and transportation planning. Additionally, StreetLight Data offers RouteScience, which organizes disparate location data into coherent travel patterns. Founded in 2012 and headquartered in San Francisco, California, the company also has offices in Richmond, Virginia, and Vancouver, Canada, and is dedicated to enhancing smart city initiatives through improved understanding of transportation behaviors.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Seismos is a data analytics company specializing in production optimization through proprietary solutions that enable real-time monitoring of underground fluid flow within reservoirs during production. Unlike conventional seismic technologies, which require months for data acquisition and processing, disrupt production, and incur high costs, Seismos offers a more efficient alternative. The company's cloud-based K-wave technology provides real-time information non-invasively, significantly reducing expenses. Additionally, Seismos develops AI-powered sensing systems that utilize non-invasive acoustic sensing and machine learning to detect and predict anomalies in various markets, including upstream, pipelines, and geothermal sectors. This allows organizations to take immediate data-driven actions.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Embodied, Inc. is a robotics company based in Pasadena, California, specializing in the development of personal companion robots aimed at enhancing care and wellness. Founded in 2016 and formerly known as CareBots, Inc., the company has created Moxie, an interactive robot designed for children that promotes social, emotional, and cognitive development through play-based learning. Drawing on over 14 years of research in socially assistive robotics from the University of Southern California and extensive experience in consumer robotics, Embodied combines advanced artificial intelligence with engaging storytelling and animation techniques. The company's mission is to improve the quality of life for individuals and families by providing life-like, interactive robots that serve as motivators, coaches, and companions, empowering users to improve their own well-being.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Ambiq Micro, Inc. is a fabless semiconductor company based in Austin, Texas, specializing in the development of ultra-low power integrated circuits tailored for power-sensitive applications. Founded in 2010, the company utilizes innovative subthreshold power optimized technology to create real-time clock and microcontroller products designed for wearables, smart cards, wireless sensors, and Internet-of-Things devices. By focusing on ultra-low-power mixed-signal solutions, Ambiq Micro aims to enhance the efficiency of wireless electronics, facilitating the creation of devices that either minimize or eliminate battery use while maximizing design flexibility. The company also provides technical support services and operates additional offices in San Jose, California, as well as in Shanghai, Shenzhen, and Taiwan.

Medisix Therapeutics, established in 2016 and headquartered in Singapore, is an early-stage biotechnology company specializing in cell therapy. It focuses on developing chimeric antigen receptor (CAR) T-cell therapies to target and treat T-cell lymphomas and leukemias. The company's technology platform is built upon the pioneering work of Professor Dario Campana, MD, PhD, a renowned expert in translational immunology and the founder of CAR-T cell biology. Medisix's proprietary immune engineering approaches enable the targeting of T cell leukemias and lymphomas using cell therapy.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Synthorx, Inc. is a biopharmaceutical company specializing in the development of innovative protein therapeutics using advanced synthetic biology techniques. Founded in 2014 and headquartered in La Jolla, California, Synthorx focuses on its proprietary Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead product candidate, THOR-707, is a modified form of recombinant human IL-2, currently being evaluated for various solid tumors both as a standalone treatment and in combination with immune checkpoint inhibitors. The company also develops Synthorins targeting IL-2 for autoimmune conditions, IL-10 for immuno-oncology applications, and IL-15 for regulating immune responses. Synthorx leverages a unique platform that enables the incorporation of synthetic DNA base pairs to enhance the specificity and efficacy of its protein therapeutics, thus offering improved treatment options for patients. Previously known as Alinos, Inc., the company acquired exclusive rights to its synthetic biology technology based on groundbreaking research from The Scripps Research Institute. As of January 2020, Synthorx operates as a subsidiary of Sanofi.